On the Way of Import Substitution
45 Drugs are manufactured at the anchor company of the Industrial Pharmaceutical Cluster of the Perm Region Medisorb.30 of them are manufactured within the framework of the import substitution program. 50% of the products are included into the list of vital and essential drugs.
The site is not going to rest on its laurels. Together with researchers from the Institute of Technical Chemistry of the Urals Affiliate of RAS its employees developed a substance for a drug against Parkinson’s disease. Clinical trials of the new substance have already been completed. The procedure of marketing authorization has begun. Development of another unique product – a drug substance for multiple sclerosis — is ongoing.
Together with colleagues from Perm State Pharma Academy and Perm Polytechnic Institute the team of Medisobr is developing a drug for AIDs and a drug for cardiovascular disorders. Cooperation on development of antidiabetic drugs and agents for treatment of locomotor system disorders has begun.
Overall six new drugs were approved within the previous year.